X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Handok is exclusively responsible for the promotion, marketing, sales and distribution of Pivlaz (clazosentan sodium), the first drug approved in South Korea for the prevention of Cerebral Vasospasm in patients with Aneurysmal Subarachnoid Hemorrhage, in South Korea.
Lead Product(s): Clazosentan Sodium
Therapeutic Area: Neurology Product Name: Pivlaz
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Sosei Group Corporation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 14, 2024
Details:
AUM-601 (CHC2014), a selective second-generation “Pan-TRK” Inhibitor was safe and well-tolerated at dose levels of 50 to 300 mg QD, as recommend Phase 2 dose (RP2D) based on PK profile and safety results.
Lead Product(s): CHC2014
Therapeutic Area: Oncology Product Name: AUM601
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: AUM Biosciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 19, 2022
Details:
CHC2014 is completing a Phase I in Korea and has shown promising data to justify advancement to a tumor agnostic registrational program. CHC2014 has shown superior in-vivo anti-tumor activity compared to available treatment options.
Lead Product(s): CHC2014
Therapeutic Area: Oncology Product Name: CHC2014
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: AUM Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 11, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
